The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis

Published:2019-01-28 Issue:2 Volume:38 Page:105-111
ISSN:1556-9527
Container-title:Cutaneous and Ocular Toxicology
language:en
Short-container-title:Cutaneous and Ocular Toxicology

Author:

Chen Peng¹,Chen Fucaho²,Zhou Benhong¹³

Affiliation:

1. Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei, P.R. China;

2. Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China;

3. School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei, P.R. China

Publisher

Informa UK Limited

Subject

Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15569527.2018.1553180

Reference37 articles.

1. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

2. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials

3. Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma

4. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success;Current Oncology Reports;2024-06-08

2. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10

3. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review;Journal of Cosmetic Dermatology;2023-03-16

4. Targeted Treatments for Cutaneous Melanoma;European Handbook of Dermatological Treatments;2023

5. The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis;European Journal of Hospital Pharmacy;2020-09-03